文献速递胸部肿瘤放疗放疗物理与技术

Ⅰ期周围型非小细胞肺癌碳离子笔束扫描放疗策略比较

Comparing Strategies for Pencil Beam Scanning Carbon Ion Radiation Therapy in Stage I Peripheral Non-Small Cell Lung Cancer: Toward Optimized Clinical Decision-Making Planning.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-08-13

单策略均改善CTV V95%但增加肺剂量;RO增加CTV V95% 4.8%-5.1%且MLD增加1.77-1.79 Gy(RBE)较ME更低。结论为无RO时推荐CTV+ME,有RO时CTV足够,DO对实性肿瘤有价值。

要点

  • 单策略均改善CTV V95%但增加患侧肺剂量,DO的MLD增加最小(0.15-0.92 Gy(RBE))
  • RO增加CTV V95% 4.8%-5.1%,MLD增加1.77-1.79 Gy(RBE),低于ME的3.78-4.86 Gy(RBE)
  • 有RO时较小margin(CTV)足够;无RO时推荐较大margin(CTV+ME),DO对实性肿瘤有价值

核心结论

  • 无RO时推荐较大margin(CTV+ME),DO建议用于实性肿瘤且在不确性下可能对GGO有益。
  • 有RO时较小margin(CTV)足够,DO对实性肿瘤仍有价值。

研究设计与样本

  • CTV为内大体肿瘤体积各向同性外扩7 mm,每例生成8个计划,组合ME(CTV+7 mm)、DO和RO三种策略。
  • 累积变形剂量由两次4D QA CT(CIRT前和中,加权5:4)计算,并评估距离和摆位不确定性的影响。

主要发现

  • 所有单策略均改善CTV V95%但增加肺剂量。
  • DO增加CTV V95% 3.3%-4.1%,MLD最小增加0.15-0.92 Gy(RBE)。
  • RO增加CTV V95% 4.8%-5.1%,MLD中度增加1.77-1.79 Gy(RBE)。
  • ME获得相似CTV增益但MLD增加最高,为3.78-4.86 Gy(RBE)。
  • GGO中CTV+RO覆盖充分且肺剂量最低;实性肿瘤中CTV+RO+DO达到接近完全覆盖,一致性改善(范围92.8%-100% vs 85.2%-100%),额外MLD仅约0.15 Gy(RBE)。

关键数值与推荐

  • 靶区覆盖以CTV V95%(接受≥95%处方剂量的CTV体积百分比)评估。
  • 患侧肺(排除内大体肿瘤体积)剂量以MLD和Vx(V5-V70,接受≥x Gy(RBE)的肺体积百分比)评估。
  • 距离不确定性通过±3.5% stopping power变化评估,摆位不确定性通过6个主方向3 mm平移评估。
  • 无RO时,CTV+ME基础上加DO可降低靶区欠剂量风险,MLD代价为-0.08至0.53 Gy(RBE)。

临床怎么用

  • 无RO时,推荐使用较大margin(CTV+ME)计划。
  • DO建议用于实性肿瘤,在不确定性下也可能对GGO有益。
  • 有RO时,较小margin(CTV)足够,DO对实性肿瘤仍有价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify the optimal planning strategy for pencil beam scanning carbon ion radiation therapy (CIRT) in stage I peripheral non-small cell lung cancer, including ground-glass opacity (GGO) and solid lesions. METHODS AND MATERIALS: Thirty patients (15 GGO and 15 solid) receiving 8 Gy (relative biological effectiveness [RBE]) × 9 fractions were analyzed. The clinical target volume (CTV) was defined as a 7-mm isotropic expansion of the internal gross tumor volume. Eight plans per patient were generated by combining 3 strategies: margin expansion (ME, CTV+7 mm), density override (DO), and robust optimization (RO). The accumulated deformed dose was calculated from two 4-dimensional quality assurance computed tomographies (pre- and mid-CIRT, weighted 5:4). Target coverage was assessed by the percentage volume of CTV receiving ≥95% prescription dose (CTV V95%); ipsilateral lung (excluding internal gross tumor volume) dose by mean lung dose (MLD) and the percentage of the lung volume receiving ≥x Gy (RBE) (Vx, V5-V70). Range and setup uncertainties were assessed by applying ±3.5% stopping power variations and 3-mm translational shifts in 6 cardinal directions, respectively, with accumulated doses generated using the same workflow. RESULTS: All single strategies improved CTV V95% but increased lung dose. DO increased CTV V95% by 3.3% to 4.1% with a minimal MLD increase of 0.15 to 0.92 Gy (RBE). RO increased CTV V95% by 4.8% to 5.1% with a moderate MLD increase of 1.77-1.79 Gy (RBE). ME yielded similar CTV gains but the highest MLD increase of 3.78 to 4.86 Gy (RBE). For GGOs, CTV+RO provided adequate coverage with the lowest lung dose. For solid tumors, CTV+RO+DO achieved near-complete coverage with improved consistency (range, 92.8%-100% vs 85.2%-100%) and a minimal additional MLD of ∼0.15 Gy (RBE). With range and setup uncertainties, results remained consistent with nominal conditions when RO was applied. In the absence of RO, the addition of DO to CTV+ME reduced the risk of target underdosage for both GGO and solid tumors at a cost of increased MLD of -0.08 to 0.53 Gy (RBE). CONCLUSIONS: This study provides quantitative data for evidence-based planning strategy selection in stage I peripheral non-small cell lung cancer receiving CIRT. Without RO, a larger margin (CTV+ME) is recommended; DO is advised for solid tumors and may also benefit GGOs under uncertainty. With RO, a smaller margin (CTV) is sufficient, and DO remains valuable for solid tumors.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lu Y, Chen J, Sheng Y, et al. Comparing Strategies for Pencil Beam Scanning Carbon Ion Radiation Therapy in Stage I Peripheral Non-Small Cell Lung Cancer: Toward Optimized Clinical Decision-Making Planning. Int J Radiat Oncol Biol Phys. 2026. PMID: 42595262. doi:10.1016/j.ijrobp.2026.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。